Royal Sense is a healthcare trading house that acts as a one-stop shop for India’s hospitals and clinics, supplying everything from surgical tools and branded drugs to rapid test kits and mobility aids without owning a single factory. Born in 2023 from the merger of three family-run medical-supply businesses whose roots stretch back to 2015, the company has spent its short listed life converting that combined sourcing know-how into a catalogue broad enough to fill a government tender or a pharmacy shelf in a single order. The recurring approach is simple: buy from vetted third-party manufacturers, put the company’s own brand on the box where it adds trust, and push the goods through every channel that reaches a patient - public e-procurement portals, a franchise pharmacy network, quick-commerce apps, and a direct sales force.
Business segments
A single trading engine that spans medical devices, pharmaceuticals, diagnostics and orthotics - one integrated supply chain feeding hospitals, government tenders and a fledgling retail pharmacy network, all built on the same sourcing-and-distribution backbone.
1. Medical supplies trading: the one-stop catalogue for Indian healthcare
The company does not manufacture anything; it sources a vast range of medical products from third parties, brands many of them under its own “STERGIC” label, and sells them to every type of healthcare buyer in India - making margin on the spread between wholesale sourcing and delivered supply.
- A catalogue built for tenders - the product range runs from surgical instruments, sutures and wound-care items to nebulizers, digital thermometers, breast pumps, walking sticks and hot-water bags, deliberately wide so that a government hospital or private clinic can fill most of a purchase order from a single supplier.
- Own brand, someone else’s factory - many products carry the registered “STERGIC” brand, for which the company holds exclusive distributor rights, while a dedicated quality-assurance team monitors the quality of products sourced from third-party suppliers.
- FDA approval as a springboard - the company secured US FDA registration for over 40 products during FY25, including three orthotic braces where it is listed as both manufacturer and repackager, opening a path to export markets without needing its own plants abroad.
- R&D means customisation, not invention - the company’s research investment goes into tailoring existing medical products for specific clinical requirements and launching new stock-keeping units; in FY25 it added more than 80 products across categories.
2. Pharmaceuticals trading: branded generics without the factory
The company buys and resells a growing formulary of branded generic drugs, antibiotics, OTC remedies and nutraceuticals, layering its own brand names onto off-patent molecules to build recognition with doctors and patients.
- A portfolio built launch by launch - the drug list includes antibiotics such as Cefix-O, Steropenam and Ugmntin, gastro-intestinal brands like Isompra DSR and RABI.SEC, and a series of multivitamin and lycopene syrups aimed at nutritional deficiencies in children, adults and the elderly.
- Moving into chronic and CNS therapies - recent launches added alprazolam (an anti-anxiety benzodiazepine), clonazepam mouth-dissolving tablets, zolpidem (a sedative-hypnotic) and a tramadol-plus-paracetamol combination painkiller, signalling a push beyond acute-care antibiotics into longer-term prescription medicines.
- The MoA tells the ambition - shareholders approved an expanded charter in September 2025 that authorises the company to deal in everything from generic drugs and vaccines to hand sanitiser and perfumes, giving legal cover to keep widening the catalogue.
3. Diagnostics and rapid test kits: private-label testing at the point of care
The company has developed its own line of rapid diagnostic test kits under the “ONCE” and “Stergic” brands, covering diseases such as dengue, typhoid, HIV and syphilis, plus a pregnancy test - all sourced from third-party manufacturers and sold into a diagnostics market that prizes speed and brand trust.
- A kit for the common fevers - the ONCE Rapid DIY range covers typhoid, chikungunya, hepatitis B surface antigen, dengue combo and pregnancy, while the Stergic Rapid line covers typhoid, chikungunya, dengue, syphilis, HIV and HBsAg.
- R&D focused on the pipeline - the company directs part of its research spending specifically at diagnostics, aiming to strengthen the range of assays and platforms it can offer.
4. Government and institutional supply: the tender-fed backbone
A dedicated channel plugs the company directly into India’s public healthcare procurement machinery - state ministries, the GEM portal and state-level tenders - turning the broad catalogue into a structural advantage because public buyers prefer vendors who can supply many line items from a single contract.
- Integrated with the government’s buying systems - the company is active on the GEM Portal and various state tender platforms, which lets it bid for supply contracts across Uttar Pradesh, Himachal Pradesh, Rajasthan and Jammu & Kashmir without building a separate sales force for each state.
- Four end-markets, one supply chain - the customer base splits into hospitals (government and private), pharmaceuticals, diagnostics, and medical equipment and supplies, with products reaching them either directly or through distributors and sub-distributors.
Stergic Pharmacy: the retail front end
A franchise-owned, company-operated pharmacy network being built under the subsidiary Stergic Retail Private Limited - the company’s bet on capturing retail margins and building a consumer brand that patients walk into, rather than one that only institutions see on a purchase order.
- FOCO model - franchisees put up the capital for the store; the company operates it and stocks it with more than 500 products from its own catalogue, giving it control over the customer experience while limiting its own real-estate costs.
- Early traction in Delhi - the first counter opened in Rohini, Delhi, in February 2026, and over 125 expressions of interest from potential franchisees were already under scrutiny at that point.
- A subsidiary with its own revenue - Stergic Retail Private Limited, which became a wholly owned subsidiary in January 2024, recorded turnover of Rs. 155.18 lakhs in its first reported period, with Royal Sense itself selling Rs. 302.38 lakhs of goods into the subsidiary.
Distribution and supply-chain backbone
A pan-India logistics network that combines regional offices, distribution centres, a direct sales force, quick-commerce partnerships and a newly leased warehouse - the physical infrastructure that lets the company promise delivery from Delhi to a remote clinic.
- Warehousing that scales with the business - the company purchased its Badli Industrial Area property in January 2025 for use as a factory-cum-corporate office, and added a five-year leased warehouse in Sonipat, Haryana, operational from February 2026, to handle growing volumes.
- Quick-commerce for medical supplies - distribution agreements with Zepto and Blinkit put products onto platforms built for 20-minute delivery, a channel most medical-supply traders do not use.
- Quality starts at the source - a dedicated sourcing team and an internal audit function run periodic checks on third-party suppliers, because the company’s brand promise rests on products it did not make itself.
- Lean headcount - as of March 2025, the entire operation ran with 68 permanent employees.
Group structure and partners
A promoter-led SME with one operating subsidiary, a related-party merger in progress, and a tightly held share register - the corporate architecture is simple but the web of related-party transactions means the business is intertwined with entities controlled by the promoter’s family.
- The subsidiary - Stergic Retail Private Limited, wholly owned since January 2024, runs the Stergic Pharmacy network and is both a customer of Royal Sense and a recipient of inter-corporate advances.
- The merger - Royal Sense is absorbing TTG Innovations Private Limited, a related party where a director has an interest, through a scheme of merger that will issue 18.1 Royal Sense shares for every one TTG share; TTG trades in pharmaceuticals and healthcare products and had turnover of Rs. 1,572.45 lakhs as of March 2025.
- Related-party dealings - in FY24, the company bought Rs. 1,382.47 lakhs of goods from TTG Innovations and sold Rs. 16.81 lakhs to a firm controlled by the promoter’s wife and Rs. 156.34 lakhs to a firm controlled by a director’s wife.
- Promoter control - Rishabh Arora held 61.50% of the equity as of July 2026 and has pledged 10 lakh shares (18.69% of total capital) as security for financial assistance to Comfort Securities Limited.